Friday 6 November 2026
Export SYK’s income statement to Excel — free account
Stryker Corporation
SYK Healthcare Medical Devices
Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024.
- Revenue
- +7.64%
- EPS
- −12.4%
- Free cash flow
- −19.4%
- Total debt
- −10.0%
Quarter to September 2026, against a year earlier
324.26
10.82
−3.23%
Follow SYK
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
41.40 | 37.64 | 32.36 | 29.14 |
P/S ratio |
5.35 | 4.98 | 4.67 | 4.00 | |
P/FCF ratio |
31.36 | 27.53 | 25.68 | 23.88 | |
P/Operating CF |
62.68 | 216.55 | 95.75 | 72.04 | |
P/B ratio |
5.99 | 5.48 | 5.03 | 4.49 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.82 | 5.44 | 5.12 | 4.45 | |
EV/EBITDA |
24.02 | 22.16 | 19.57 | 17.61 | |
EV/Operating CF |
28.96 | 25.60 | 23.93 | 21.47 | |
EV/FCF |
34.11 | 30.10 | 28.12 | 26.52 | |
Quick Ratio |
1.04 | 1.04 | 1.08 | 1.07 | |
Current Ratio |
1.89 | 2.11 | 2.16 | 2.18 | |
Net Debt/EBITDA |
5.55 | 9.51 | 5.87 | 8.77 | |
Debt/Assets |
33.15% | 31.81% | 31.17% | 31.60% | |
Debt/Equity |
0.71 | 0.64 | 0.62 | 0.64 | |
Asset Turnover |
0.55 | 0.55 | 0.55 | 0.56 | |
Operating CF/Net income |
2.52 | 0.78 | 0.99 | 1.94 | |
Capex/Depreciation |
(1.37) | (0.55) | (0.68) | (0.80) | |
Interest Coverage |
11.71 | 6.32 | 11.77 | 7.23 | |
Research and Development Expense of Revenue |
5.59% | 6.86% | 6.59% | 6.64% | |
Selling, General and Administrative Expense of Revenue |
31.06% | 37.89% | 33.83% | 35.48% | |
Intangible Assets out of Total Assets |
0.52 | 0.53 | 0.53 | 0.53 | |
Share Based Compensation of Revenue |
0.67% | 1.45% | 0.82% | 1.03% | |
Graham Net Nets |
(0.08) | (0.08) | (0.08) | (0.09) | |
Graham Number |
105.86 | 108.57 | 117.02 | 114.23 | |
Earnings Yield |
2.42% | 2.66% | 3.09% | 3.43% | |
Free Cash Flow Yield |
3.19% | 3.63% | 3.89% | 4.19% | |
Revenue per Share |
18.76 | 15.72 | 17.18 | 17.06 | |
Operating CF per Share |
5.61 | 1.52 | 3.29 | 3.82 | |
Capex per Share |
(1.13) | (0.43) | (0.53) | (0.62) | |
Free Cash Flow per Share |
4.47 | 1.08 | 2.76 | 3.20 | |
Cash per Share |
10.73 | 7.74 | 9.06 | 8.56 | |
Shareholders Equity per Share |
58.66 | 60.01 | 62.55 | 61.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
58.66 | 60.01 | 62.55 | 61.37 | |
Free Cash Flow |
1,710.00 | 415.00 | 1,059.00 | 1,224.00 | |
Working Capital |
6,961.00 | 7,023.00 | 7,734.00 | 7,683.00 | |
Capital Expenditures |
(433.00) | (166.00) | (202.00) | (237.00) | |
Net Current Asset Value |
(10,669.00) | (9,974.00) | (9,524.00) | (9,607.00) | |
EV/EBIT |
29.88 | 27.58 | 23.89 | 21.52 | |
Capex to Sales |
0.06 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
27.48 | 25.22 | 21.82 | 19.37 | |
| Other line items | |||||
Average Receivables |
4,013.00 | 3,766.00 | 3,830.50 | 3,668.00 | |
Average Payables |
1,739.00 | 1,528.00 | 1,552.50 | 1,566.00 | |
Average Inventory |
5,042.00 | 5,262.00 | 5,405.00 | 5,558.50 | |
Average Assets |
45,407.50 | 46,148.50 | 47,130.50 | 47,152.00 | |
Average Common Equity |
21,527.00 | 21,954.50 | 22,589.50 | 22,621.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026